Resource
Dear Reader
A Message from the President
Scientific & Clinical
IMF Launches Bank On a Cure
Revlimid Where Do We Stand?
Bortezomib as Treatment as MM: Analysis of Efficacy and Toxicity…
Resource
Dear Reader
A Message from the President
Scientific & Clinical
Program Highlights from the 10th International Workshop in Myeloma
2005 Brian D. Novis Research Grants
Update on Lenalidomide (CC-…
Resource
This research focuses on unifying a multiple myeloma staging system around the world called the International Staging System (ISS). Information was taken from 10,750 myeloma patients previously untreated from North America, Asia, and Europe. The results of testing three different assessments for…
Resource
Dear Reader
A Message from the President
Scientific & Clinical
IMF Celebrates Landmark Success of 2004
Medicare Reform Targets Cancer for Cost Savings
New Developments in Multiple Myeloma…
Resource
Message from IMF President
Why Bank On A Cure®?
Treating Multiple Myeloma: The Little Rock Approach
The Genetics of Multiple Myeloma
Drug Resistance: Overcoming Multiple Myeloma Drug Resistance by Inhibiting the…
Resource
Message from IMF President
Advocacy Update: Congress Adjourns with Support for Myeloma Community
ASH 2003: An Avalanche of New Information
News & Notes
2004 Brian D. Novis Research Grant Awards
…
Resource
Saluting an Incredible Human Being:
Dr. Robert A. Kyle Receives Lifetime Achievement Award
Myeloma Patients and Oncology Nurses to Benefit from IMF/Millennium Collaboration
The IMF Visits Italy and France
Early studies…
Resource
These consensus guidelines have been compiled with input from the Scientific Advisors of the International Myeloma Foundation. Their production involved several steps including:
A 3-day Scientific Advisors meeting, during which each specific area was presented and discussed (May 2002…
Resource
Dear Reader
Ask the Expert
The Pathogenesis and Treatment of Multiple Myeloma Bone Disease
The Good, the Bad, and the Ugly of Cancer Public Policy
IMFer Profile
Terry Herman Shares…
Resource
Dear Reader
FDA Approves VELCADE® for the Treatment of Relapsed and Refractory Multiple Myeloma
Profile Interview: Julian Adams, Ph.D.
Life Lessons from a Politician
Myeloma Update: Overview of the 9th…
Resource
Report from the Los Angeles IMF Patient & Family Interactive Seminar/strong>
Dear Reader
Ask the Expert: Staying Well During Chemotherapy
Indiana University Cancer Research Center…
Resource
Dear Reader
Ribbon of Hope — Making a World of Difference
IMF 12th Anniversary Gala
Did You Know?
Immunizations in myeloma patients
The Gift of Good Nutrition
Ask the…
Resource
Dear Reader
IMF Support Group Leaders’ Retreat 2002
Friends We Never Hoped to Meet
Ask the Expert: Dr. Steve Schey Answers Your Questions
Legal Assistance for the Cancer Patient…
Resource
IMF World Events
Dear Reader
Neuropathy and Monoclonal Gammopathy
Developing the Second Generation Myeloma Chip
PS-341: The Patient Experience
Multiple Musicians Against Multiple Myeloma…
Resource
Dear Reader
IMF President Susie Novis Testifies Before Senate Appropriations Subcommitee
OVAC 2002 Advocacy Day Senate Hearing: Oral Testimony of Susie Novis
NCI Director Andrew von Eschenbach's Speech Highlights Patient-Family…
Resource
The Importance of Knowing the Potential Outcome: Role for the new International Prognostic Index (IPI)
Ask the Experts: Genetic Testing to Determine The Cause and Outcome of Myeloma
Bench to the Bedside: Is it a Myth?
After Any Diagnosis
Gala 2002 Honoree: Daniel E.…
Resource
Dear Reader
The IMF Presents: Myeloma Matrix
Ask the Experts: Infection in Multiple Myeloma
Book Review: Living Proof
IMFer Profile: Lee Grayson…
Resource
Autologous Hematopoietic Stem Cell Transplantation by J-L Harousseau
Bone Marrow and Peripheral Blood Stem Cell Transplantation by G. Gahrton
Myeloma Today Profile: Dr. Joan Blade and Prof. Jesus San Miguel
Stem Cell…
News Article
International Myeloma Foundation (IMF) and International Myeloma Working Group (IMWG) to Honor 2026 Kyle and Durie Achievement Awardees, Dr. Hermann Einsele and Dr. Noopur RajeAwarding ceremonies to be held today, June 9, 2026, at the 17th Annual IMWG Summit in Stockholm, Sweden.STOCKHOLM,…
Page
Double Your Impact. Help More People Affected by Myeloma.Many employers offer matching gift programs that can double—or even triple—the value of your donation. By submitting a matching gift request, you can help fund more research, provide more free educational resources, and support more families…
News Article
Sarclisa (isatuximab) SC — the first anticancer therapy approved by the European Union (EU) to be administered through an on-body injector (OBI) — "can provide the flexibility of administration at patients’ homes and in the outpatient setting." On Monday, June 8, Sanofi announced in a…
Blog post
Shining a Light on Scientists’ Vital Work in Multiple Myeloma CareThis blog was written by IMF Support Group Leader and multiple myeloma patient Terry Glassman.I’ve been a multiple myeloma patient for almost three and a half years now. Myeloma is a complex and nuanced disease; because of that, we…
Page
Advancing access, accelerating research, and improving outcomes in myeloma care.The U.S. Myeloma Network (USMN) is a national clinical trials and education initiative designed to accelerate the development of innovative treatments for multiple myeloma while expanding equitable access to research…
Videos
What Are Trispecific Antibodies in Multiple Myeloma? | Myeloma in a Minute What are trispecific antibodies, and how could they affect multiple myeloma treatment? In this quick explainer video, Dr. Joseph Mikhael breaks down the difference between bispecific antibodies and emerging trispecific…
IMF Person
Jennifer Schlesinger has spent more than 20 years working in the public sector and with nonprofit health organizations. She has overseen professional training and outreach programs, community and health education, healthcare advocacy, and technical assistance and support to healthcare systems…
Blog post
Based on Data from Pivotal Myeloma Clinical Trials, The Amazing New “Normal” in Myeloma Is Here for Today’s Patients By Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO IMF Medical Advisor Scope and Methodology StatementThis article was…
Blog post
Key Takeaways from the Facebook Live Q&A: Dr. Sagar Lonial Answers Your Myeloma Questions Dr. Sagar Lonial, a member of the IMF Scientific Advisory Board and the IMF International Myeloma Working Group, answers myeloma questions in a summary of the Facebook Live held on March 25, 2026.Dr.…
Blog post
A summary of some notable key multiple myeloma research from March-April 2026 Scope and Methodology This week’s blog summarizes key multiple myeloma research published in several peer-reviewed publications and medical journals March-April 2026. Content was…
Event
Join the International Myeloma Foundation for a FREE special webinar bringing together leading voices in myeloma to break down the most important updates from:ASCO (American Society of Clinical Oncology)…
Videos
How Long Will I Live With Multiple Myeloma? | Myeloma Expert Answers in a Minute or Less"How long will I live with myeloma?" It's one of the first questions patients and families ask after diagnosis. In this video, myeloma expert Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO, explains…
Blog post
AI Is Already Shaping Healthcare, But How Are People Actually Using It? According to the article, “The Future of Healthcare: AI, Public Health and the Digital Revolution,”…
Blog post
Drs. Joseph Mikhael and Melissa Alsina Answer Myeloma Questions — a Summary of the March 14, 2026, Facebook Live On Saturday, March 14, IMF Medical Advisor Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, along with associate professor of medicine in the Blood and Marrow Transplant Program at…
Blog post
From Early Warning Signs to a 14-Year Watch-and-WaitThe International Myeloma Foundation continues to share this collection of patient and care partner stories from those who have completed the Legislative Advocacy Master Class (LAMC). The IMF hopes that these unique and compelling stories will…
Blog post
IMF Director of Public Policy & Advocacy Danielle Doheny breaks down barriers to care and the reasons why the International Myeloma Foundation’s (IMF) Advocacy Team is actively working to ensure timely, affordable, and equitable access for all patients. By Danielle Doheny…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the May 2026 edition.The IMF team of medical editors has provided overviews of key studies. Yet, we encourage…
Blog post
A summary of some notable key multiple myeloma research from February-March 2026 Scope and Methodology This week’s blog summarizes key multiple myeloma research published in several peer-reviewed publications and medical journals February-March 2026.…
Videos
What Happens After CAR T-Cell Therapy? Myeloma Experts Answer Common QuestionsWhat happens to your immune system after CAR T-cell therapy? How long should patients stay on lenalidomide maintenance? And how do people keep track of all their myeloma labs, medications, and treatment changes?In this…
Blog post
Shifting Perspectives After a Multiple Myeloma DiagnosisThe International Myeloma Foundation continues to share this collection of patient and care partner stories from those who have completed the Legislative Advocacy Master Class (LAMC). The IMF hopes that these unique and compelling stories will…
Blog post
Show the world that you are #MoreThanMyeloma this 2026 Myeloma Action Month! Light the world red and participate in month-long IMF events this March. This year, the International Myeloma Foundation (IMF) is inviting the global myeloma community to demonstrate the spirit of #…
Blog post
The 2025 IMF Latin American Myeloma Network (LAMN) Master Class and Summit took place on November 14–15, 2025, in Santiago, Chile. By Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO IMF Chief Medical Officer …
Blog post
A summary of some notable key multiple myeloma research from January-February 2026Scope and Methodology This week’s blog summarizes key multiple myeloma research published in several peer-reviewed publications and medical journals from January-February 2026. Content was…
Blog post
One Patient Hopes His Voice Will Raise Overall Myeloma AwarenessThe International Myeloma Foundation continues to share this collection of patient and care partner stories from those who have completed the Legislative Advocacy Master Class (LAMC). The IMF hopes that these unique and compelling…
Blog post
Best of ASH 2025: IMF Chief Medical Officer Dr. Joseph Mikhael’s Top 10 Multiple Myeloma Abstracts By Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO IMF Chief Medical Officer Scope and Methodology This week’s blog is…
Blog post
ASCO’s Updated Living Guideline for Multiple Myeloma: FAQs and Key Updates Scope and Methodology This week’s blog answers frequently asked questions (FAQs) about the recently published updated living guideline on the treatment of multiple myeloma — a…
Blog post
A summary of some notable key multiple myeloma research from December 2025 to January 2026 Scope and Methodology This week’s blog summarizes key multiple myeloma research published in several peer-reviewed publications and medical journals from December 2025 -…
Blog post
Finding Meaning in the American Society of Hematology Annual Meeting & ExpositionI start with a heartfelt thank you to the IMF for bringing the patients to science so we can bring the science to the patients!When I first attended American Society of Hematology (ASH) Annual Meeting &…
Videos
Can You Live a Normal Life With Multiple Myeloma? Real Answers From Myeloma Experts What happens after a multiple myeloma diagnosis? What questions should you ask your doctor? And can people actually live normal lives with myeloma today?In this video, Dr. Joseph Mikhael and Beth Faiman answer…
News Article
We Are #MoreThanMyeloma on Capitol HillBy Danielle Doheny, IMF Director, Public Policy & AdvocacyDuring Myeloma Action Month (MAM) in March 2026, the International Myeloma Foundation (IMF) brought patients, care partners, and advocates to Capitol Hill, ensuring that the voices…
Blog post
ASH 2025 Multiple Myeloma Updates: What the Latest Research Means for Patients and Care Partners Scope and Methodology This week’s blog summarizes key takeaways from the Top Myeloma Research Presented at ASH 2025: Easy-to-Understand Insights for Patients…